Cite
A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study.
MLA
Español-Rego, Marta, et al. “A Phase I-II Multicenter Trial with Avelumab plus Autologous Dendritic Cell Vaccine in Pre-Treated Mismatch Repair-Proficient (MSS) Metastatic Colorectal Cancer Patients; GEMCAD 1602 Study.” Cancer Immunology, Immunotherapy : CII, vol. 72, no. 4, Apr. 2023, pp. 827–40. EBSCOhost, https://doi.org/10.1007/s00262-022-03283-5.
APA
Español-Rego, M., Fernández-Martos, C., Elez, E., Foguet, C., Pedrosa, L., Rodríguez, N., Ruiz-Casado, A., Pineda, E., Cid, J., Cabezón, R., Oliveres, H., Lozano, M., Ginés, A., García-Criado, A., Ayuso, J. R., Pagés, M., Cuatrecasas, M., Torres, F., Thomson, T., … Maurel, J. (2023). A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study. Cancer Immunology, Immunotherapy : CII, 72(4), 827–840. https://doi.org/10.1007/s00262-022-03283-5
Chicago
Español-Rego, Marta, Carlos Fernández-Martos, Elena Elez, Carles Foguet, Leire Pedrosa, Nuria Rodríguez, Ana Ruiz-Casado, et al. 2023. “A Phase I-II Multicenter Trial with Avelumab plus Autologous Dendritic Cell Vaccine in Pre-Treated Mismatch Repair-Proficient (MSS) Metastatic Colorectal Cancer Patients; GEMCAD 1602 Study.” Cancer Immunology, Immunotherapy : CII 72 (4): 827–40. doi:10.1007/s00262-022-03283-5.